---
document_datetime: 2025-08-13 15:41:05
document_pages: 6
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: exparel-liposomal-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 3.6063696
conversion_datetime: 2025-12-26 17:12:15.989456
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## EXPAREL liposomal

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| PSUSA/10889 /202310  | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                          | 16/05/2024                          | n/a                                         |                                  | PRAC Recommendation - maintenance |
| II/0018              | B.II.c.1.d - Change in the specification parameters and/or limits of an excipient - Change outside the approved specifications limits range | 21/03/2024                          | n/a                                         |                                  |                                   |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10889 /202304   | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                                                                                                                                                                           | 30/11/2023   | n/a   | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------------------------|
| IAIN/0017             | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                           | 03/11/2023   | n/a   |                                     |
| IA/0016               | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                 | 12/10/2023   | n/a   |                                     |
| IB/0014               | B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)                                                                                                                                                               | 16/08/2023   | n/a   |                                     |
| IB/0013/G             | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                    | 06/06/2023   | n/a   |                                     |
| PSUSA/10889 /202210   | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                                                                                                                                                                           | 12/05/2023   | n/a   | PRAC Recommendation - maintenance   |
| II/0011/G             | This was an application for a group of variations. B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product | 04/05/2023   | n/a   |                                     |

<div style=\"page-break-after: always\"></div>

|                     | B.II.b.3.b - Change in the manufacturing process of the finished or intermediate product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product                                                                                                                                                                                                                                                                                                                                                                                                                                   |            |            |             |                                                                                  |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------|
| PSUSA/10889 /202204 | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 01/12/2022 | n/a        |             | PRAC Recommendation - maintenance                                                |
| II/0005             | Extension of indication to include treatment of children aged 6 and older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds for EXPAREL liposomal; as a consequence, sections 4.1,4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP). C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | 15/09/2022 | 07/11/2022 | SmPC and PL | Please refer to Scientific Discussion EXPAREL liposomal EMEA/H/C/004586/II/0005. |
| PSUSA/10889 /202110 | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 05/05/2022 | n/a        |             | PRAC Recommendation - maintenance                                                |
| IB/0009/G           | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 19/04/2022 | n/a        |             |                                                                                  |

<div style=\"page-break-after: always\"></div>

|           | specification limits B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the   |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0006   | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/12/2021 | n/a |
| IA/0007/G | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 22/11/2021 | n/a |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| A.z - Administrative change B.II.d.2.a - Change in test product - Minor changes procedure B.II.c.1.a - Change in the and/or limits of an excipient specification limits B.I.b.1.b - Change in the and/or limits of an AS, starting material/intermediate/reagent specification limits B.II.c.1.a - Change in the and/or limits of an excipient specification limits B.I.b.1.d - Change in the and/or limits of an AS, starting material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.b - Change in the and/or limits of an AS, starting material/intermediate/reagent specification limits B.I.b.1.d - Change in the and/or limits of an AS, starting material/intermediate/reagent significant specification an obsolete parameter) B.II.c.1.c - Change in the and/or limits of an excipient significant specification   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| IB/0004/G           | This was an application for a group of variations. B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure                                                                                                                        | 29/10/2021   | n/a   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| PSUSA/10889 /202104 | Periodic Safety Update EU Single assessment - bupivacaine (liposomal formulations)                                                                                                                                                                                             | 28/10/2021   | n/a   | PRAC Recommendation - maintenance |
| IB/0002/G           | This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure | 13/07/2021   | n/a   |                                   |